A5058368410- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Liver physiology and pathology
- Brain Metastases and Treatment
- Cancer Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- RNA and protein synthesis mechanisms
- Bioinformatics and Genomic Networks
- Renal cell carcinoma treatment
- Immunotherapy and Immune Responses
- RNA modifications and cancer
- Lymphoma Diagnosis and Treatment
- Gastrointestinal disorders and treatments
- Lymphatic Disorders and Treatments
- Eosinophilic Disorders and Syndromes
- Phagocytosis and Immune Regulation
- Bladder and Urothelial Cancer Treatments
- Fractal and DNA sequence analysis
- Metastasis and carcinoma case studies
- DNA Repair Mechanisms
- Immune cells in cancer
City Of Hope National Medical Center
2020-2025
Cedars-Sinai Medical Center
2024
City of Hope
2019-2024
Beckman Research Institute
2020
Weatherford College
2020
Lung cancer can be classified into two main categories: small cell lung (SCLC) and non-small (NSCLC), which are different in treatment strategy survival probability. The CT images of SCLC NSCLC similar such that their subtle differences hardly visually discernible by the human eye through conventional imaging evaluation. We hypothesize SCLC/NSCLC differentiation could achieved via a computerized feature analysis classification. purpose this study was to use radiomics differentiate from...
The usefulness of circulating tumor DNA (ctDNA) in detecting mutations and monitoring treatment response has not been well studied beyond a few actionable biomarkers non-small cell lung cancer (NSCLC).
EGFR-mutated lung adenocarcinoma patients who received tyrosine kinase inhibitors (TKIs) may initially respond to therapy, but over time, resistance eventually occurs. In a small population (5-10%), these can have histological transformation SCLC. Nine with transformed SCLC were evaluated at City of Hope. Patient clinical and pathology data, including multiple next-generation sequencing (NGS) results, therapies, histology, outcomes, collected across time points. Descriptive statistics...
Lung cancer is the leading cause of cancer-related death in both men and women with over 130,000 deaths more than 220,000 new cases expected each year United States 1 Siegel RL Miller KD Wagle NS Jemal A. Cancer statistics, 2023. CA J Clin. 2023; 73: 17-48 Crossref PubMed Scopus (695) Google Scholar . Eighty to ninety percent newly diagnosed are Non-Small Cell (NSCLC) 50% those being histologically adenocarcinoma 2 Servetto A Esposito D Ferrara R et al. RET rearrangements non-small cell lung...
Tyrosine kinase inhibitors (TKIs) are now the standard of care first-line therapy for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC) patients. Despite positive outcomes in most patients, with extended progression-free survival (PFS), a small population patients respond poorly to these drugs. Complex genetic and non-genetic resistance mechanisms may be drivers disease cancer, but further research is required identify clinic. Germline molecular...
Introduction Immune checkpoint inhibitors (ICIs) produce a broad spectrum of immune-related adverse events (irAEs) affecting various organ systems. While ICIs are established as therapeutic option in non-small cell lung cancer (NSCLC) treatment, most patients receiving ICI relapse. Additionally, the role on survival prior targeted tyrosine kinase inhibitor (TKI) therapy has not been well-defined. Objective To investigate impact irAEs, relative time occurrence, and TKI to predict clinical...
Background: The molecular and clinical features of KRAS-mutated lung cancer patients treated with immunotherapy have yet to be characterized, which could guide the development therapeutics targeting KRAS potential immuno-oncology treatment combinations. Research Question: Do different subtypes comutations responses overall survival (OS) checkpoint inhibitors? Study Design Methods: 87 NSCLC at City Hope who received immune inhibitors were identified analyzed retrospectively. Tumor genomic...
PURPOSE Leptomeningeal disease (LMD) is associated with significant morbidity and mortality for metastatic non–small cell lung cancer (NSCLC). We describe our clinical experience in evaluating the use of cerebrospinal fluid (CSF)–derived circulating tumor cells (CTCs) diagnosis LMD detection genomic alterations CSF cell-free DNA (cfDNA). METHODS Patients NSCLC who had collection as part routine care suspected were included study. was evaluated CTCs cfDNA using a commercial assay (CNSide;...
Patients reporting high PD-L1 expression have shown to respond well immunotherapy; however, some patients develop hyperprogressive disease upon initiation of immune checkpoint inhibitors. We report a patient with lung cancer and 100% who developed while treated pembrolizumab responded salvage chemotherapy carboplatin pemetrexed.A 66-year-old African American female 25-pack year smoking history, diabetes mellitus type 2, essential thrombocytosis, history papillary thyroid carcinoma relapsed...
Metastasis continues to be the primary cause of all cancer-related deaths despite recent advancements in cancer treatments. To evaluate role mutations overall survival (OS) and treatment outcomes, we analyzed 957 metastatic patients with seven major types who had available molecular testing results a FoundationOne CDx® panel. The most prevalent genes somatic were TP53, KRAS, APC, LRP1B. In this analysis, these mutation frequencies higher than publicly datasets. We identified that mutually...
Abstract We conducted spatial immune tumor microenvironment (iTME) profiling using formalin-fixed paraffin-embedded (FFPE) samples of 25 KRAS -mutated non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitors (ICIs), including 12 responders and 13 non-responders. An eleven-marker panel (CD3, CD4, CD8, FOXP3, CD68, arginase-1, CD33, HLA-DR, pan-keratin (PanCK), PD-1, PD-L1) was used to study the compositions. Spatial features at single level cellular neighborhoods fractal...
Acute kidney injury (AKI) has been well described as a complication of immune checkpoint inhibitor therapy. We present series patients, the majority with lung adenocarcinoma, who developed AKI while actively receiving inhibitors.
Immune checkpoint inhibitors (ICIs) have changed the landscape of lung cancer therapy. However significant proportions patients primary or acquired resistance to ICIs. Molecular characterization is critical for patient selection and overcoming inhibitors. The purpose this study investigate molecular characteristics associated with ICIs outcomes in advanced non-small cell (NSCLC) patients.
Omic-informed therapy is being used more frequently for patients with non-small-cell lung cancer (NSCLC) treated on the basis of evidence-based decision-making. However, there a lack standardized framework to evaluate those decisions and understand association between omics-based management strategies survival among patients. Therefore, we compared outcomes adenocarcinoma who received omics-driven targeted versus standard therapeutic options.This was retrospective study advanced NSCLC (N =...
Immune-related adverse events (IRAEs) are a common yet problematic phenomenon in patients who treated with immune checkpoint inhibitors (ICIs). Current research efforts have explored the exact pathophysiology of IRAEs clinical setting. However, rare subset that is less highlighted and may cause detrimental effects hematological (heme-IRAEs). Of note, immune-induced eosinophilia itself heme-IRAE worthy further investigation. In this report, we present two cases advanced staged non-small cell...
Oncology has become more reliant on new testing methods and a greater use of electronic medical records, which provide plethora information available to physicians researchers. However, take advantage vital clinical research data for precision medicine, we must initially make an effort create infrastructure the collection, storage, utilization this with uniquely designed disease-specific registries that could support collection large number patients.In study, perform in-depth analysis series...
The complexity of cancer care requires integrated and continuous support to deliver appropriate care. An expert network with complementary expertise the capability multidisciplinary is an integral part contemporary oncology Appropriate infrastructure necessary empower this personalized precision their patients. Providing decision as becomes exponentially more complex new diagnostic therapeutic choices remains challenging. City Hope has developed a Pyramidal Decision Support Framework address...
Non-small cell lung cancer is a devastating disease and with the advent of targeted therapies molecular testing, decision-making process has become complex. While established guidelines pathways offer some guidance, they are difficult to utilize in busy community practice not always implemented community. The rationale study was identify cohort patients adenocarcinoma at City Hope site (n = 11) their case studies develop framework utilizing fast-and-frugal tree (FFT) heuristics. Most had...